Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.42 |
| ▸ | TYR | P14679 | 4/20 | 0.41 |
| ▸ | GJB2 | P29033 | 1/20 | 0.40 |
| ▸ | IGF2R | P11717 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161927 | 0.92 | GJB2 (0.46) | LGALS8LGALS3LGALS4GJB2IGF2R | |
| SCHEMBL20161635 | 0.92 | GJB2 (0.46) | LGALS8LGALS3LGALS4GJB2IGF2R | |
| SCHEMBL20161454 | 0.89 | LGALS8 (0.42) | LGALS8LGALS3LGALS4TYRGJB2 | |
| SCHEMBL20161920 | 0.87 | PYGB (0.43) | CA12CA1CA2CA9 | |
| SCHEMBL20161290 | 0.87 | PYGB (0.43) | CA12CA1CA2CA9 | |
| SCHEMBL20161302 | 0.87 | PYGB (0.43) | CA12CA1CA2CA9 | |
| SCHEMBL20161463 | 0.86 | LGALS3 (0.46) | LGALS8LGALS3LGALS4TYRIGF2R | |
| SCHEMBL20161936 | 0.84 | LGALS3 (0.49) | LGALS8LGALS3LGALS4TYRIGF2R | |
| SCHEMBL21342377 | 0.84 | LGALS3 (0.49) | LGALS8LGALS3LGALS4TYRIGF2R | |
| SCHEMBL20161294 | 0.82 | LGALS3 (0.46) | LGALS8LGALS3LGALS4TYRIGF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | L'OREAL (FR) | 2021-06-29 | — | — | US | disclosed |
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | L'OREAL (FR) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133137-A1 | PROCESS FOR TREATING KERATIN MATERIALS USING AMIDE, ACID OR ESTER C-GLYCOSIDE DERIVATIVES, AND COSMETIC COMPOSITION CONTAINING SAME | KRT18, CUTA, GLA | LGALS8 270/4885LGALS3 403/4885LGALS4 351/4885 |
| US-11045411-B2 | Process for treating keratin materials using amide, acid or ester c-glycoside derivatives, and cosmetic composition containing same | KRT18, CUTA, GLA | LGALS8 270/4885LGALS3 403/4885LGALS4 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.